Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sanofi US
GSK and Sanofi will continue to defend against all claims alleging ranitidine increased risk of cancer. Four Rx generic firms reach settlements in first case scheduled for trial. Former US OTC Zantac marketers GSK and Sanofi, which markets the Zantac OTC brand in the US, along with former Rx brand marketer Pfizer could pay $1bn to $2bn each in potential settlements, analyst predicts.
GlaxoSmithKline will continue to defend itself against all claims alleging ranitidine increased the risk of cancer. Four generic firms reach settlements in the first case that had been scheduled for trial. GSK, Sanofi and Pfizer could pay $1bn-$2bn each in potential settlements, an analyst predicts.
Biden Administration officials pledge ongoing efforts to thwart manufacturer restrictions on 340B drug discounts, but at the same time urge hospitals to be more transparent about how they use the savings.
Private sector efforts to lower cost sharing for insulin continue but patient advocates and lawmakers still believe legislation is needed to tackle the issue in a comprehensive way.